Report
Kelsey Tsai
EUR 147.86 For Business Accounts Only

Specialty Pharma Industry Faces Tough Times; Wide-Moat Allergan Remains Our Top Pick

The specialty pharmaceuticals industry remains turbulent due to several industrywide headwinds--increasing customer buying power, more generic competition from a decline in the FDA backlog, fewer large patented drugs coming off patent, and rumors of collusion charges for some generic firms. In addition, the industry faces many company-specific self-inflicted wounds such as Valeant’s Philidor debacle, criticism of Mylan’s EpiPen price hikes, and Perrigo’s botched integration of Omega. With the ex...
Underlying
Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals is a pharmaceutical company engaged in developing, manufacturing, and marketing a range of branded and non-branded generic pharmaceutical products across the U.S., the Middle East and North Africa, and Europe. Co.'s business segments are: Injectables, which sells specialized generic injectable products, including sterile liquid, powder, lyophilized and cytotoxic products; Generics, which sells non-injectable generic products that include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone; and Branded products, which sells branded generics and in-licensed products including Amoclan®, Blopress®, Omnicef®, Prograf® and Suprax®.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Kelsey Tsai

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch